Impact of Obesity on Warfarin Reversal With Fixed-Dose Factor VIII Inhibitor Bypassing Activity (aPCC).

Amanda L McKinneyLindsey M DaileyJames C McMillenAnthony Shaun Rowe

Published in: The Annals of pharmacotherapy (2020)

When fixed-dose aPCC is used for warfarin reversal, obesity is associated with a significantly lower rate of INR reversal, without increased bleeding. This study adds to the limited amount of literature on aPCC dosing in obesity.

Keyphrases

insulin resistance
metabolic syndrome
weight loss
atrial fibrillation
high fat diet induced
type diabetes
weight gain
venous thromboembolism
direct oral anticoagulants
oral anticoagulants
physical activity